ScientiaLux
Index
QF-Pro Home › QF-Pro Glossary › aFRET
Assay Type

aFRET

TSA-enhanced FRET methodology for measuring intramolecular activation states–quantifying kinase phosphorylation and conformational changes within individual proteins.

View
Definition
amplified FRETLoading... (aFRET) uses tyramide signal amplificationLoading... to detect intramolecular FRET events–conformational changes within a single protein that indicate activation state. The canonical application is detecting kinase activation through phosphorylation-induced conformational changes, where FRET occurs between two epitopes on the same protein brought into proximity by phosphorylation.
Video Segments
Amplified FRET: Solving the Tissue Problem
Primary
Post-Translational Modifications via aFRET
Primary
Phosphorylation detection
Kinase activation state
Conformational change
Intramolecular FRET
TSA amplification
10–100× signal enhancement
Validated targets
PKB/Akt, receptor tyrosine kinases

Intramolecular vs Intercellular FRET

While iFRETLoading... measures interactions between two proteins, aFRET measures changes within a single protein. When a kinase like Akt/PKBLoading... is activated by phosphorylation at T308, conformational changes bring specific epitopes closer together–close enough for FRET to occur between donor and acceptor chromophoresLoading... attached to antibodies targeting these epitopes.

This approach reports on protein function rather than expression: an inactive kinase and an active kinase both express the same protein, but only the active form shows FRET.

Simplified

Two Types of Measurement:

• aFRET (amplified FRET): Measures changes WITHIN a single protein—like detecting if a protein has changed shape to become "active"

• iFRET (intercellular FRET): Measures connections BETWEEN proteins on different cells—like checkpoint interactions at the immune synapse

The Akt/PKB Paradigm

Akt/PKB activation at T308 was the first aFRET application validated in clinical samples. In breast cancer and renal cell carcinoma, Akt activation measured by FRET efficiencyLoading... correlated with poor prognosis–while Akt expression by conventional IHCLoading... showed no prognostic value.

This demonstrates the core principle: measuring how much protein is present (expression) tells you less than measuring what that protein is doing (activation state).

Simplified

The Proof of Concept: Akt activation was the first target validated by aFRET in clinical samples.

Key Finding: In breast cancer and kidney cancer, measuring whether Akt was "turned on" predicted patient survival. Measuring how much Akt protein was present told doctors nothing useful.

This established the principle: activation state provides information that expression cannot.

Clinical Applications

Clinically Validated

Intracellular Activation States: Amplified FRET (aFRET) measures conformational changes and phosphorylation states within individual proteins–capturing functional activation rather than expression.

The PKB/Akt validation studies established aFRET as a prognostic tool: activation state predicts survival where expression fails. In breast cancer (n=164) and ccRCC (n=60), only FRET-measured activation correlated with patient outcomes.

Simplified

Clinical proof: aFRET measures whether proteins are switched on, not just present. In over 200 patients across breast and kidney cancer, activation state predicted who would survive–expression measurements missed this entirely.

Clinical Applications

  • Akt/PKBLoading... activation predicts survival in breast cancerLoading... where expression does not
  • Oncoprotein activation state provides functional layer beyond expression profiling
  • Enables detection of pathway activation in tumors with wild-type genotype

Connected Terms

Share This Term
Term Connections